Drug therapy of inflammatory arthritis

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 12, Issue 4, 2012, Pages 357-363

  Gullick, Nicola J ^a   Scott, David L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Ankylosing spondylitis; Biologics; DMARDs; Drug therapy; Inflammatory arthritis; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ALEFACEPT; ANALGESIC AGENT; AZATHIOPRINE; CANNABIS; CAPSAICIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NEFOPAM; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; ARTICLE; BEHCET DISEASE; BIOLOGICAL THERAPY; BURNING SENSATION; CLINICAL FEATURE; CLINICAL PRACTICE; DOPPLER FLOWMETRY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; ENTEROPATHY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFLAMMATORY ARTHRITIS; LONG TERM CARE; LOW DRUG DOSE; MIXED CONNECTIVE TISSUE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OUTCOME ASSESSMENT; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SPONDYLOARTHROPATHY; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TENOSYNOVITIS; TOXIC HEPATITIS; TUBERCULOSIS; ULTRASOUND; UNSPECIFIED SIDE EFFECT; X RAY;

EID: 84865495402     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.12-4-357     Document Type: Article

References (51)

1. Aletaha D, Neogi T, Silman AJ et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
2. Backhaus M, Kamradt T, Sandrock D et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum 1999;42:1232-45. (Pubitemid 29268961)
3. Schirmer M, Duftner C, Schmidt WA, Dejaco C. Ultrasonography in inflammatory rheumatic disease: an overview. Nat Rev Rheumatol 2011;7:479-88.
4. Marzo-Ortega H, McGonagle D, Bennett AN. Magnetic resonance imaging in spondyloarthritis. Curr Opin Rheumatol 2010;22:381-7.
5. van Venrooij WJ, van Beers JJBC, Pruijn GJM. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011;7:391-8.
6. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
7. Whittle SL, Richards BL, Husni E, Buchbinder R. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev 2011;(11):CD003113.
8. Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2012;(1):CD008921.
9. Richards BL, Whittle SL, Buchbinder R. Antidepressants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2011;(11):CD008920.
10. Ramiro S, Radner H, van der Heijde D et al. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011;(10):CD008886.
11. Gaujoux-Viala C, Smolen JS, Landewe R et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.
12. National Institute for Health and Clinical Excellence. Rheumatoid arthritis. Clinical guideline 79. London: NICE, 2009.
13. Choy EH, Smith C, Doré C, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005;44:1414-21. (Pubitemid 41631866)
14. Kingsley G, Kowalczyk A, Taylor H et al. A randomized placebo-controlled trial of MTX in PsA Rheumatology 2012 doi: 10.1093/rheumatology/kes001.
15. Ash Z, Gaujoux-Viala C, Gossec L et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2011;71:319-26.
16. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14:340-3. (Pubitemid 30479708)
17. Kirwan J, Bijlsma JWJ, Boers M et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;(1):CD006356.
18. Capell H, Madhok R, Hunter J et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004;63:797-803. (Pubitemid 38850450)
19. Buttgereit F, Doering G, Schaeffler A et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371:205-14.
20. Singh JA, Christensen R, Wells GA et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Can Med Assoc J 2009;181:787-96.
21. van der Heijde D, Kavanaugh A, Gladman DD et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-707. (Pubitemid 47237288)
22. National Institute for Health and Clinical Excellence. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. Technology appraisal 199. London: NICE, 2010.
23. National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for ankylosing spondylitis. Technology appraisal 143. London: NICE, 2008.
24. Goldring S, Gravellese E. Mechanisms of bone loss in inflammatory arthritis. Arthritis Res 2000;2:33-7.
25. Steen KSS, Nurmohamed MT, Visman I et al. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:256-9. (Pubitemid 351183319)
26. Adabayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? J Postgrad Med 2009;82:186-91.
27. Bjornsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005;40:1095-101. (Pubitemid 41291360)
28. Lacaille D, Guh D, Abrahamowicz M et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
29. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1157-60. (Pubitemid 47050621)
30. Lane MA, McDonald JR, Zeringue AL et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine 2011;90:139-45.
31. Saillot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68:25-32.
32. Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
33. Solovic I, Sester M, Gomez-Reino J et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1186-206.
34. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738-45.
35. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9. (Pubitemid 46764070)
36. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275-85.
37. Smolen JS, Aletaha D, Bijlsma JWJ et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
38. Schoels M, Knevel R, Aletaha D et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
39. van Tuyl L, Boers M, Lems WF et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010;69:807-12.
40. Verschueren PEG, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008;47:59-64. (Pubitemid 350286263)
41. Gullick N, Oakley S, Zain A et al. Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. Rheumatology (Oxford) 2012;51:759-61.
42. University of Leeds. Tight control of psoriatic arthritis (TICOPA). Bethesda (MD): National Library of Medicine (US), 2010. http://clinicaltrials. gov/ct2/show/NCT01106079 [Accessed 31 May 2012].
43. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
44. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009;22:56-60.
45. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
46. Song I-H, Heldmann F, Rudwaleit M et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011;70:1108-10.
47. Song IH, Heldmann F, Rudwaleit M et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62:1290-7.
48. Yazici Y, Regens AL. Promising new treatments for rheumatoid arthritis: the kinase inhibitors. Bull NYU Hosp Jt Dis 2011;69:233-7.
49. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
50. Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
51. Braun J, van den Berg R, Baraliakos X et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.